CureVac NV
5CV
Company Profile
Business description
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Contact
Friedrich-Miescher-Strasse 15
TubingenBW72076
DEUT: +49 707198830
E: sarah.fakih@curevac.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,088
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,585.00 | 1.70 | -0.02% |
| CAC 40 | 7,734.40 | 130.04 | -1.65% |
| DAX 40 | 23,629.58 | 369.59 | -1.54% |
| Dow JONES (US) | 41,603.07 | 256.02 | -0.61% |
| FTSE 100 | 8,717.97 | 21.29 | -0.24% |
| HKSE | 23,326.25 | 275.01 | -1.17% |
| NASDAQ | 18,737.21 | 188.53 | -1.00% |
| Nikkei 225 | 37,329.22 | 168.75 | 0.45% |
| NZX 50 Index | 12,553.78 | 42.72 | -0.34% |
| S&P 500 | 5,802.82 | 39.19 | -0.67% |
| S&P/ASX 200 | 8,356.70 | 4.20 | -0.05% |
| SSE Composite Index | 3,336.70 | 11.67 | -0.35% |